NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets reduced their target price on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Performance

NBY opened at $0.49 on Thursday. NovaBay Pharmaceuticals has a one year low of $0.36 and a one year high of $10.15. The stock has a market capitalization of $2.40 million, a P/E ratio of -0.01 and a beta of 0.69. The business’s 50-day simple moving average is $0.64 and its 200-day simple moving average is $1.07.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.